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Engraftment failure and graft-versus-host disease (GVHD) serve
as major impediments to successful clinical bone marrow trans-
plantation (BMT). We have previously shown in a murine model
that supplementing puriﬁed allogeneic hematopoietic stem cells
(SC) with a population of CD8dTCR bone marrow-de-
rived cells results in markedly enhanced engraftment and complete
donor chimerism across full MHC barriers. Unlike T cells, these
facilitating cells (FC) do not result in GVHD even in semi-allo-
geneic parent3F1 aggressive GVHD models. Recent reports have
suggested that GVHD can be suppressed by the administration of
ex-vivo expanded CD4CD25 regulatory T cells. Although the
FC is not a T cell, we hypothesized that FC-mediated tolerance
may result from a similar mechanism. In order to investigate the
unmitigated GVHD effector activity of the FC, puriﬁed donor SC
and FC inocula were transplanted within a semi-allogeneic, hap-
loidentical model of lethal GVHD. Unlike T-cell recipients that
succumbed to lethal GVHD, all FC-recipients were free from any
evidence of GVHD. Analysis of the recipient splenocytes revealed
a signiﬁcant up-regulation of regulatory T-cell genes CTLA4,
GITR and FoxP3, suggesting that the inhibition of GVHD in a
semi-allogeneic model was coupled to an in vivo induction of
regulatory T-cells. To further delineate this FC-coupled effect in
a fully allogeneic murine BMT model, lethally irradiated B10.BR
recipients were transplanted with SCFC derived from C57BL/6
(B6) murine bone marrow (BM), while lethally irradiated B6 re-
cipients transplanted with B6-derived SC alone served as radiation
controls since SC alone or SCTBM(BM derived T-cells) fail to
engraft in fully allogeneic recipients when the FC is absent. The
fully allogeneic SCFC recipients displayed excellent engraftment
and complete donor chimerism without GVHD. Surprisingly, a
signiﬁcant number of CD4CD25regulatory T-cells (2.3 	
0.23%) were detected by ﬂow cytometric analysis of splenocytes
harvested from these SCFC allogeneic recipients. Of even
greater interest, was the marked increase of this regulatory T-cell
subset (2.2 	 0.9%) in the BM of FC recipients compared with
negligible regulatory cell presence in the BM of syngeneic B6
control recipients (0.27%). For the ﬁrst time, our studies indicate
that FC-mediated alloengraftment and lack of GVHD in a fully
allogeneic murine model occurs in association with the induction
of regulatory T-cells in vivo.
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THE RESULTS OF RISK ADAPTED PRE-EMPTIVE THERAPY OF CMV
INFECTION WITH GANCICLOVIR IN 169 PATIENTS, AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HEMATOLOGY-
ONCOLOGY AND BMT RESEARCH CENTER
Iravani, M.; Faghih, A.H.; Shamshiri, A.R.; Toutounchi, M.; Tavakoli,
M.; Mousavi, A.; Bahar, B.; Alimoghadam, K.; Jahani, M.; Gha-
vamzadeh, A. Hematology-Oncology and BMT Research Center, Tehran
University of Medical Science, Tehran, Islamic Republic of Iran.
During an 18 month period, we studied on 169 allogeneic HSCT
in Hematology- Oncology and BMT Research Center, Tehran
University of Medical Sciences. Patients were evaluated for PP.65
CMV antigen by immuno ﬂuorescence method every 10–14 days
during ﬁrst 100 post-transplant days. 74 patients had positive test
for at least one time. We treated 41 asymptomatic patients by
risk-adapted pre-emptive therapy strategy with ganciclovir. Higher
age at the time of transplant, non sibling and HLA mismatch
transplant, disease for which transplant was done (AML and CML
vs. ALL and thalassemia), grade of acute GVHD, higher maximum
cyclosporine level, systemic steroid consumption, and pre-trans-
plant immunosuppressive regimen (MTX and cyclosporine vs. cy-
closporine alone) all had association with antigenemia. Event free
survival in 100 and 180 post transplant days were 90% and 84%,
respectively. There was no signiﬁcant difference between ﬁrst 100
post transplant days mortality of patients with and without anti-
genemia, and patients with and without pre-emptive ganciclovir
treatments. Mortality in30180 post-transplant days of patients
with ganciclovir treatment was higher than without treatment
group. Ganciclovir effectively omitted antigenemia in 98% of pa-
tients. In 64% of patients, there was not antigenemia relapse after
pre-emptive therapy. Asymptomatic antigenemia relapse and
symptomatic antigenemia relapse occurred in 28% and 8% of
patients respectively. 57% of relapses were early and 43% were
late. Leukopenia was the major side effect of ganciclovir therapy.
47% of patients used at least one dose of GCSF. Pre-treatment
leukocyte count predicted post-treatment leukocyte count in pa-
tients.
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MYELOABLATIVE CONDITIONING WITH FLUDARABINE AND BUSULFAN
FOR ALLOGENEIC PBSCT IN CHRONIC PHASE CML
Iravani, M.; Tavakoli, M.; Shamshiri, A.R.; Mousavi, A.; Bahar, B.;
Jahani, M.; Ghavamzadeh, A. Hematology-Oncology and BMT Re-
search Center, Tehran University of Medical Science, Tehran, Islamic
Republic of Iran.
We have studied a regimen comprising intravenous ﬂudarabine
(40 mg/m2 on days 6 to 2) plus oral busulfan (4 mg/kg/day on
days 5 to 2) as a new conditioning regimen for allogeneic
peripheral blood stem cell transplantation in 16 CML patients in
chronic phase with matched related donors. Cyclosporine was used
as a prophylactic agent for GVHD (3 mg/kg IV till 4, 10 mg/kg
oral from day 5). 15 (94%) patients had standard and one had
high risk CML. The median patient age was 32 years (range,
11–43). The median follow-up was one year (range, 119–517
days). There was no cardiac toxicity and hemorrhagic cystitis.
Grade 1–2 and grade 3 mucositis occurred in 75% and 25%
respectively and 31% developed hepatic toxicity which resolved
with conservative therapy. 37.5% experienced moderate to severe
headache. The median of highest serum creatinine level during
hospitalization were 1.5 mg/dl (range, 1–3.6; 25% with Cr2) and
serum cyclosporine level, at the same time, was 158 ng/ml (range,
9–429). Incidence of acute GVHD grade 1–2 and grade 3 were
37.5% and 19% respectively. Grade 4 acute GVHD was found in
one patient. 50% showed limited chronic GVHD. 31% of patients
became CMV (min 48, max 69). The median times for neu-
trophil and platelet recovery were 11 (min 0, max19) and 14 (min
0, max 30) days. In day 38, 87.5% of the patients had 90% or
more, mononuclear chimerism (with STR-PCR technique; me-
dian, 100%; range, 93–100). There was no molecular relapse.
Nonrelapse mortality was 25% (4 patients; acute GVHD grade
IV1, CMV infection and GVHD1, pneumonia1, infec-
tion1). With a median follow up of one year (range, 4–17
months), the probabilities of overall survival and disease free sur-
vival were both 75%. In another study in our center, using busulfan
and cyclophosphamide as standard conditioning regimen for 112
CML patients in chronic phase, the probability of overall survival,
with the same median time of follow up, was 53.57%. So it seems
that ﬂudarabine could be well tolerated in standard conditioning
regimen versus cyclophosphamide for patients with standard risk
CML in chronic phase, but it deserves further studies to establish.
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IN VIVO T CELL DEPLETED UNRELATED ALLOGENEIC STEM CELL
TRANSPLANTATION WITH A REDUCED INTENSITY REGIMEN IN PA-
TIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES
Magalhaes-Silverman, M.; Carter, T.; Gingrich, R.; Hohl, R.; Schlu-
eter, A. University of Iowa, Iowa City, IA.
Background:Graft versus host disease (GVHD) remains a major
cause of mortality after transplantation. Reduced intensity condi-
tioning (RIC) regimens followed by allogeneic stem cell transplan-
tation (SCT) with in vivo T-cell depletion using Campath-1H have
been shown to decrease the incidence of GVHD. We report our
experience with such an approach in 19 patients (pts) with ad-
vanced hematologic malignancies undergoing unrelated SCT.
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Patients and Methods: Nineteen pts with a median age of 56
years (range 18–70) not eligible for ablative SCT received
Campath-1H 20 mg/m2, ﬂudarabine 25 mg/m2  5 days and
either cyclophosphamide 1 g/m2  2 days (n16 pts), melpha-
lan 140 mg/m2 (n1 pt) or busulfan 0.8 mg/m2  8 doses (n2
pts) followed by G-CSF stimulated peripheral blood (n13) or
unmanipulated bone marrow(n6). GVHD prophylaxis con-
sisted of CSA at least until T60 and mycophenolate mofetil
through T30. DLI was allowed for residual/progressive dis-
ease or mixed chimerism after T60 in absence of GVHD.
Seven pts had a previous autologous transplantation. Ten pts
had myeloid diseases (AML6, CML Ph negative1, CML
accelerated phase1, therapy related MDS1, myeloﬁbro-
sis1); 9 pts lymphoid (HD3, NHD5, PLL1); only 5 pts
were in CR at transplant. Six pts received bone marrow with a
median CD34 cells infused of 3.7  106/kg, and 13 pts pe-
ripheral blood with a median of 4.5  106/kg CD34 cells
infused. Results:19 achieved ANC 0.5  106/L within a
median of 12 days (range 8–16); 2 pts rejected the graft and 1
had autologous reconstitution; 10/19 achieved sustained platelet
engraftment at a median of 16 days (range 7–27). 2/17 pts with
sustained engraftment developed acute GVHD; 7/14 at risk pts
had CMV reactivation; TRM at T100 was 16% (disease pro-
gression in 2 and GVHD in 1). Nine pts received DLI (5 for
persistent mixed chimerism and 4 pts for persistent/progressive
disease). After DLI 5 pts had GVHD limited to skin. Of the pts
with myeloid malignancies 2 pts remain alive in CR at T28,
19 months; of the pts with lymphoid malignancies 2 pts with
HD are alive in CR at T34, 15 months and 2 pts with mantle
cell lymphoma are alive at T19, T13 months. Causes of
death include disease progression in 7 pts, CMV disease in 1 pt,
adenovirus/CMV disease in 1 pt, sepsis in 1 pt and GVHD in 3
pts. Conclusion: These results suggest that this approach is well
tolerated with a low early TRM even in pts with advanced
disease. Longer follow-up and better patient selection are
needed.
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UMBILICAL CORD BLOOD TRANSPLANTS (UCBT). EVALUATION OF
CHIMERISM AND SURVIVAL IN RELATION TO CD34 OR MONONUCLEAR
CELL (MNC) DOSE INFUSED. THE CHILDREN’S MEMORIAL HOSPITAL
(CMH) EXPERIENCE
Merchant, M.1; Olszewski, M.1; Duerst, R.1,2; Huang, W.1; Jacobsohn,
D.1,2; Kletzel, M.1,2 1. Children’s Memorial Hospital, Chicago, IL; 2.
Northwestern University Feinberg School of Medicine, Chicago, IL.
To evaluate chimerism and to determine if cell dose/kg has a
relationship with time to full chimerism in children undergoing
Hematopoietic UCBT unrelated (n85) related (n3) at CMH;
between 1995 and 2004, one hundred and one UCBT were per-
formed at CMH of those 88 meet the study criteria (survive 30
days post transplant) to be evaluable for engraftment and survival.
There were patients (pts) with malignant (n71) and non-malig-
nant (17) diseases with a mean age of 5.0 years (.6–16) and a mean
weight of 20.2 kg (5.6–61). The preparative regimen consisted of
fTBI (1200 cGy) day 8 to 5, VP-16 1000 mg/m2 day 4 and
cyclophosphamide 60 mg/kg/day days 3 to 1. GVHD prophy-
laxis consisted of CSA, short course MTX, ATG (days 1, 3, 5, 7).
Engraftment was deﬁned as the time to reach 95% donor chi-
merism, assessed by either ﬂuorescence in-situ hybridization or
variable number tandem repeats (VNTRs). Cell counts were mea-
sured by the Abbott Cell Dyne counter and the CD34 cells were
quantiﬁed by ﬂow cytometry on a FACS sorter. Pts were divided in
two groups according to cell doses received (
.7 or .7) for
CD34  106/kg and MNC  108/kg cells. Statistical analysis was
made by a non-parametric t test and column statistics (mean 	
SEM and all were at the 95% CI) on (Graph Pad). The overall
engraftment of the 88 patients was 72% (63/88). There was no
difference among the groups in volume infused, malignant or
non-malignant or the status of disease prior to transplant. Pts with
the lower CD34 and MNC cells infused were heavier and showed
a lower incidence of full chimerism and a trend to slower engraft-
ment. There was also a survival difference in favor of the higher
CD34 cell infused group.
Table 1. CD34  106/kg MNC  108/kg
Cell Doses <.7 >.7 p Value <.7 >.7 p Value
Age 6.8  0.8 4.0  3.6 0.002 6.6  0.5 2.2  .45 <0.0001
Weight 25.7  2.4 17.2  1.3 0.0015 24.8  1.6 12.5  1.1 <0.0001
Days to >95%
chimerism 37.3  4.6 30.8  2.9 0.2 34.8  3.3 29.6  3.7 0.3
% achieving full
chimerism 52.9 83.3 0.001 56.8 78.0 0.02
% Overall
survival 44.1 61.6 0.001 53.4 56.6 n/s
Number of
patients 34 54 58 30
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HEMATOPOIETIC CELL TRANSPLANTATION (HCT)-SPECIFIC-COMOR-
BIDITY INDEX: A NEW TOOL FOR RISK ASSESSMENT BEFORE ALLO-
GENEIC HCT
Sorror, M.L.1; Maris, M.B.1,2; Storb, R.F.1,2; Baron, F.1; Sandmaier,
B.M.1,2; Maloney, D.G.1,2; Barry, S.E.1,2 1. Fred Hutchinson Cancer
Research Center; 2. University of Washington, Seattle, WA.
We have reported on the use of Charlson comorbidity index
(CCI) to predict non-relapse mortality (NRM) and overall survival
(OS) for patients (pts) given nonablative or ablative HCT1. How-
ever, the sample size of pts with scores of1, captured by the CCI,
did not exceed 35%. Further, some of comorbidities were rarely
found among pts given HCT. Therefore, we sought to develop an
HCT-speciﬁc-comorbidity index aimed at a) better deﬁning pre-
viously identiﬁed comorbidities, i.e. adding pulmonary functions
tests to pulmonary, liver function tests to hepatic, and ejection
fraction 50% to cardiac comorbidities and b) investigating addi-
tional HCT-related comorbidities. To this end, we retrospectively
reviewed comorbidities of 1055 pts given HCT at our center
between 1997–2003 after nonablative (n294) or ablative (n761)
conditioning. Pts were randomly divided into training (n708) and
validation sets (n347). In the training set, the unadjusted hazard
ratios (HR) for 2-year NRM were calculated for each comorbidity
and then adjusted for other comorbidities, disease risk, and condi-
tioning type. The adjusted HRs were employed as weights for
individual comorbidities. Differences encountered compared to
the original CCI were: a) two new comorbidities were added
(obesity  score 1 and peritransplantation infection  score 2), b)
age 50 years acquired a score of 2, and c) hypertension and
asthma each acquired a score of 1 instead of 0, moderate pulmo-
nary, peptic ulcer, and rheumatologic each acquired a score of 2
instead of 1, valvular heart disease a score of 2 instead of 0, and
severe pulmonary comorbidity a score of 3 instead of 1. In the
training set, HR for NRM for scores 0, 1, 2, 3, 4, 5 were 1, 1.2,
3.5, 6.1, 7.1, and 10.8, respectively. The modiﬁed index was then
validated using the validation set. This index had the advantage of
1) capturing more pts with high scores and 2) distinguishing pts
with low scores who had lower NRM and better OS when com-
pared to the original CCI (Table). Applying the scores to nonab-
lative and ablative pts, respectively, NRM of 5 vs 10% (p0.4) and
OS of 85% vs 75% (p0.1) were seen for scores of 0–1, 17 vs 27%
(p0.04) and 61 vs 59% (p0.2) for scores of 2–3, and 33 vs 54%
(p0.03) and 43 vs 30% (p0.006) for scores of 4. This HCT-
speciﬁc comorbidity index provides a simple, readily applicable and
valid method of estimating NRM and OS among pts given nona-
blative or ablative allogeneic HCT. (1. Sorror et al. Blood. 2004;
104:961.)
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